ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: 0731 • ACR Convergence 2020

    Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U

    Jackeline Rodriguez-Smith1, Virginia Miraldi Utz2, Amy Cassedy1, Sherry Thornton1, Grant Schulert3, Alyssa Sproles4, Najima Mwase1, Theresa Hennard1, Mekibib Altaye2, Alexei Grom1 and Sheila Angeles-Han1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children's Hospital Medical Center, Cincinnati, 3PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital, Cincinnati

    Background/Purpose: The pathogenesis of pediatric uveitis remains unclear. Studies of biomarkers using aqueous humor (AqH) identified S100 proteins, cytokines, and chemokines as potential biomarkers of…
  • Abstract Number: 1408 • ACR Convergence 2020

    Metabolic Reprogramming in Memory CD4+ T Cells Is Associated with Immune Cell Dysfunction During Aging

    Yuling Chen1, Yuanchun Ye2, Hao Wu3, Pierre-Louis Krauß1, Pelle Löwe1, Moritz Pfeiffenberger1, Lisa Ehlers1, Thomas Buttgereit4, Paula Hoff5, Frank Buttgereit6 and Timo Gaber1, 1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology and Tumor Immunology, Berlin, Germany, 3Julius-Maximilians Universität Würzburg, Institut für Systemimmunologie, Würzburg, Germany, 4Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venerology, and Allergology, Berlin, Germany, 5Endokrinologikum Berlin, Rheumatologie, Berlin, Germany, 6Charité University Medicine, Berlin, Germany

    Background/Purpose: Inflamm-aging is a chronic, sterile, low-grade inflammatory status, characterized by an increase of proinflammatory cytokines which participate in the development of most age-related diseases…
  • Abstract Number: 0745 • ACR Convergence 2020

    Development of Functional Assays to Pre-qualify Human Mesenchymal Stem Cells for Rheumatoid Arthritis Treatment

    Maya Breitman1, Tracey Bonfield2, Arnold Caplan3, Hillard Lazarus4, Maricela Haghiac5, Jane Reese6 and Nora Singer1, 1The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, 2National Center of Regenerative Medicine Case Western Reserve University School of Medicine, Cleveland, OH, 3Skeletal Research Center Case Western Reserve University School of Medicine, Cleveland, OH, 4Case Western Reserve University School of Medicine, Cleveland, OH, 5The MetroHealth System, Cleveland, OH, 6University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Sero-positive rheumatoid arthritis (RA) is a chronic autoimmune disease that without effective treatment, leads to joint damage and disability. Not all patients respond to…
  • Abstract Number: 1414 • ACR Convergence 2020

    Highly Polyfunctional Metabolically Altered Pathogenic T Cells Accumulate in the Synovial Tissue of RA Patients and Arthralgia Subject but Not Healthy Control Synovial Tissue

    Achilleas Floudas1, Barry Moran2, Nuno Neto3, Michael Monaghan4, Vinod Krishna5, Sunil Nagpal6, Phil Gallagher7, Conor Hurson8, Douglas Veale9 and Ursula Fearon10, 1Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, 2Trinity Biomedical Sciences Institute, Dublin, Ireland, 3Department of Mechanical and Manufacturing Engineering, Dublin, Dublin, Ireland, 4Department of Mechanical and Manufacturing Engineering, Dublin, Ireland, 5Janssen R&D, Spring House, PA, 6Janssen Research & Development, Collegeville, PA, 7St Vincents University Hospital, UCD, Dublin, Ireland, 8St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, 9EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, 10Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland

    Background/Purpose: Effective treatment of Rheumatoid arthritis (RA) patients is achievable within a short window of opportunity following diagnosis. Identification of pathogenic immune mechanisms at a…
  • Abstract Number: 0751 • ACR Convergence 2020

    Serum Interferon-Alpha Levels Could Help Identify a Subgroup of Rheumatoid Arthritis with Poorer Physical Function and Higher Physician Global Assessment

    Yong Gil Hwang1, Lei Zhu2, Dongwen Wu2 and Larry Moreland3, 1University of Pittsburgh Physicians, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of Colorado, Colorado

    Background/Purpose: Our objective was to identify the clinical significance of serum interferon-alpha levels in patients with established rheumatoid arthritis (RA).Methods: Serum samples and clinical data…
  • Abstract Number: 1449 • ACR Convergence 2020

    Altered Splicing in Leukocytes from Patients with Antiphospholipid Syndrome, Systemic Lupus Erythematosus and Antiphospholipid Syndrome with Lupus: Clinical Involvement

    Alejandra Maria Patiño-Trives1, Alejandro Ibáñez-Costa2, Carlos Pérez-Sánchez1, Laura Pérez-Sanchez3, Maria Luque-Tevar1, Iván Arias de la Rosa1, María-Carmen Abalos-Aguilera1, Desirée Ruiz-Vilchez4, Pedro Segui5, Mario Espinosa5, Nuria Barbarroja1, Eduardo Collantes4, Justo P. Castaño5, Raul M Luque5, María de los ángeles Aguirre-Zamorano5 and Chary Lopez-Pedrera1, 1Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, 2IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, 3Hospital Universitario Reina Sofía, Córdoba, Spain, 4Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 5IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba

    Background/Purpose: To identify shared and differential changes in the splicing machinery of immune cells from antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome…
  • Abstract Number: 0777 • ACR Convergence 2020

    CLEC12A Expression as a Potential Predictor of Disease Activity in Early Rheumatoid Arthritis

    Myriam Vaillancourt1, Philippe Desaulniers1, Guillaume Paré1, Nathalie Pagé1, Asmaa Lachaab1, Anthony Kerever1, Anne-Sophie Julien1, Nathalie Amiable1, Martin Pelletier1, Philippe Tessier1, Louis Bessette2, Paul Fortin3, Laetitia Michou1 and Maria Fernandes1, 1Université Laval, Québec, QC, Canada, 2Laval University, Quebec, Canada, 3CHU de Quebec - Universite Laval, Quebec, Canada

    Background/Purpose: Rheumatoid arthritis (RA) develops as a result of the dysregulation of immune activating and inhibitory pathways. Several lines of evidence indicate that inhibitory receptors…
  • Abstract Number: 1484 • ACR Convergence 2020

    Efficacy of Tocilizumab in Patients with Hand Osteoarthritis: Double Blind, Randomized, Placebo Controlled, Multicenter Trial

    Pascal Richette1, Augustin Latourte2, Jeremie Sellam3, Daniel Wendling4, Muriel Piperno5, Philippe Goupille6, Yves-Marie Pers7, Florent Eymard8, Sebastien Ottaviani9, Paul Ornetti10, Rene-Marc Flipo11, Bruno Fautrel12, Jean-Pierre Bertola13, Eric Vicaut14 and Xavier Chevalier15, 1Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, 2Department of Rheumatology, Lariboisière Hospital, AP-HP Université de Paris, INSERM U1132, Paris, France, 3AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, 4CHU Besançon, department of rheumatology, Besancon, France, 5Rheumatology Department, Lyon University Hospital, Lyon, France, 6CHU Tours, department of rheumatology, Tours, France, 7IRMB, University of Montpellier, Inserm U1183, University Hospital of Montpellier, Montpellier, France, 8APHP Henri Mondor Hospital, Creteil, France, 9Rheumatology Department, Bichat hospital, APHP, Paris, France, 10CHU Dijon, INSERM CAPS 1093, plateforme d’investigation technologique CIC1432, Dijon, France, 11Lille University Hospital, Lille, France, 12Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, 13CHUGAI PHARMA FRANCE, Paris, France, 14Clinical Research Unit, Paris, 15AP-HP, UPEC, Créteil

    Background/Purpose: To evaluate the efficacy of tocilizumab, an antibody against interleukin-6 receptor (IL-6R), in patients with hand osteoarthritis.Methods: This was a multicenter, 12-week, randomized, double-blind,…
  • Abstract Number: 0003 • ACR Convergence 2020

    Assessing Cytokine Profiles and COVID Serology in Patients on Immunosuppression to Guide Care Recommendations

    Quinn Pritchett1, Rebecca Overbury1, Dorota Lebiedz-Odrobina1, Julie Thomas1, Tawnie Braaten2, Stacey Clardy1, Marc Elgort3, Emily Spivak1, Patricia Slev3, Lisa Peterson3 and Tracy Frech4, 1University of Utah, Salt Lake City, UT, 2University of Utah, Salt Lake City, 3ARUP, Salt Lake City, UT, 4University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT

    Background/Purpose: The COVID-19 pandemic is especially terrifying for patients on immunosuppression for autoimmune disease. With the exception of social isolation, experts do not have clear…
  • Abstract Number: 0791 • ACR Convergence 2020

    Peficitinib Inhibits Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes

    Yuzo Ikari1, Takeo Isozaki1, Kuninobu Wakabayashi1 and Tsuyoshi Kasama2, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan

    Background/Purpose: Peficitinib is a novel Janus kinase (JAK) inhibitor developed for the treatment of rheumatoid arthritis (RA). Peficitinib has approved in 2019 in Japan, but…
  • Abstract Number: 1511 • ACR Convergence 2020

    Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort

    Melissa Munroe1, Kendra Young2, Jill Norris3, Joel Guthridge4, Diane Kamen5, Timothy Niewold6, Gary Gilkeson7, Michael Weisman8, Mariko Ishimori9, Daniel Wallace10, David Karp11, John Harley12 and Judith James13, 1Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, 2University of Colorado Denver, Aurora, CO, 3Colorado School of Public Health, Aurora, CO, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Medical University of South Carolina, Charleston, SC, 6NYU School of Medicine, New York, NY, 7Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 8Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, 9Cedars-Sinai Medical Center, Los Angeles, CA, 10Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, 11UT Southwestern Medical Center, Dallas, TX, 12Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, 13Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK

    Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…
  • Abstract Number: 0065 • ACR Convergence 2020

    The Energy-dependent Hierarchy of Immune Functions in Human Monocytes

    Pierre-Louis Krauß1, Thomas Buttgereit2, Yuling Chen1, Moritz Pfeiffenberger1, Timo Gaber1 and Frank Buttgereit3, 1Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, 2Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venerology, and Allergology, Berlin, Germany, 3Charité University Medicine, Berlin, Germany

    Background/Purpose: At sites of inflammation, monocytes carry out specific immunological functions while facing challenging bioenergetic restrictions. Here, we investigated the potential of human monocytes to…
  • Abstract Number: 0851 • ACR Convergence 2020

    Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature

    Peter Lipsky1, Ronald van Vollenhoven2, Thomas Dörner3, Victoria Werth4, Joan Merrill5, Richard Furie6, Milan Petronijevic7, Benito Velasco Zamora8, Maria Majdan9, Fedra Irazoque-Palazuelos10, Robert Terbrueggen11, Nikolay Delev12, Michael Weiswasser12, Shimon Korish12, Nataliya Agafonova12, Mark Stern13, Sarah Hersey13, Ying Ye13, Allison Gaudy12, Zhaohui Liu12, Shaojun Tang13 and Peter Schafer12, 1RILITE Foundation, Charlottesville, VA, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3DRFZ and Charité University Hospitals, Berlin, Germany, 4University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 7Military Medical Academy, Belgrade, Serbia, 8Instituto CER S.A., Buenos Aires, Argentina, 9Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, 10Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, 11DxTerity Diagnostics Inc, Rancho Dominguez, 12Bristol Myers Squibb, Princeton, 13Bristol-Myers Squibb, Princeton

    Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
  • Abstract Number: 1523 • ACR Convergence 2020

    Pulmonary Cytokine, Chemokine and Growth Factor Profiles of Distinct Radiographic Patterns of Interstitial Lung Disease in Systemic Sclerosis

    Elizabeth Volkmann1, Donald Tashkin2, Ning Li2, Mei Leng2, Grace Kim2, Jonathan Goldin2, Airi Harui2 and Michael Roth2, 1University of California, Los Angeles, Los Angeles, CA, 2University of California, Los Angeles, Los Angeles

    Background/Purpose: The radiological hallmarks of systemic sclerosis-related interstitial lung disease (SSc-ILD) include interstitial inflammation (ground glass opacity) with reticular changes (fibrosis). The precise pathobiology of…
  • Abstract Number: 0095 • ACR Convergence 2020

    Systematic Evaluation of Nine Monogenic Autoinflammatory Diseases Reveals Common and Disease-Specific Correlations with Allergy-Associated Features

    Moses Kitakule1, Brian Dizon2, Cristhian Gutierrez-Huerta1, Sarah Blackstone2, Aarohan Burma1, Aran Son1, Natalie Deuitch1, Sofia Rosenzweig1, Hirsh Komarow1, Deborah Stone3, Anne Jones4, Michele Nehrbecky1, Patrycja Hoffmann5, Tina Romeo6, Adriana de Jesus7, Sara Alehashemi8, Megha Garg9, Sofia Torreggiani10, Gina Montealegre Sanchez11, Katelin R. Honer10, Karyl Barron1, Ivona Aksentijevich4, Amanda Ombrello12, Raphaela Goldbach-Mansky13, Daniel Kastner14, Joshua Milner15, Pamela Frischmeyer-Guerrerio1 and Daniella Schwartz16, 1National Institutes of Health, Bethesda, 2National Institutes of Health, BETHESDA, MD, 3NIH, Bethesda, 4National Human Genome Research Institute, Bethesda, MD, 5NIH, Vienna, VA, 6NIH, Bethesda, MD, 7Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, 8Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, 9NIH/NIAID, Rochester, NY, 10Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 11NIAID/NIH, Rockville, MD, 12National Human Genome Research Institute/National Institutes of Health, Bethesda, MD, 13Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD, 14National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD, 15Division of Allergy, Immunology and Rheumatology Columbia University Medical Center, New York, NY, 16National Institutes of Health Clinical Center, Bethesda, MD

    Background/Purpose: Monogenic autoinflammatory diseases (AID) are caused by mutations in innate immune signaling genes. The effect of these mutations on the risk of allergy is…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology